Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk

被引：34

作者：

Linton M.R.F. ^{[1
]}

Fazio S. ^{[1
]}

机构：

[1] Departments of Medicine, Pharmacology, and Pathology, Vanderbilt University Medical Center, Nashville, 37232, TN

来源：

Current Atherosclerosis Reports | 2000年 / 2卷 / 1期

关键词：

Coronary Heart Disease Risk; Fenofibrate; Gemfibrozil; Lovastatin; Statin;

D O I：

10.1007/s11883-000-0092-2

中图分类号：

学科分类号：

摘要：

It is now widely accepted that low-density lipoprotein (LDL) is not the only atherogenic component of the lipid profile and that abnormalities in the metabolism and plasma levels of triglycerides and high-density lipoprotein (HDL) may lead to accelerated growth of atherosclerotic lesions. Fibrates are the drugs of first choice in the management of hypertriglyceridemia, and are also able to substantially raise HDL. The recently published Veterans Administration-High-density Lipoprotein Intervention Trial (VA-HIT) trial showed that fibrate treatment in patients with coronary heart disease (CHD), low HDL, modestly elevated triglycerides, and normal LDL reduces the risk of a recurrent coronary event by 25%. A reasonable approach to the dyslipidemic patient with high CHD risk is to tailor the intervention to the specific lipoprotein abnormality. Under these assumptions fibrate therapy should become widespread, considering that the most common lipid alteration in CHD and patients with diabetes is low HDL and high triglycerides. © 2000, Current Science Inc.

引用

页码：29 / 35

页数：6

共 50 条

[1]

Witztum J.L., Drugs used in the treatment of hyperlipoproteinemias, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, pp. 875-897, (1996)

[2]

W.H.O. cooperative trial on primary prevention of ischæmic heart disease using clofibrate to lower serum cholesterol: mortality follow-up, Lancet, 2, pp. 379-385, (1980)

[3]

Austin M.A., Hokanson J.E., Edwards K.L., Hypertriglyceridemia as a cardiovascular risk factor, Amer J Cardiol, 81, pp. 7B-12B, (1998)

[4]

Brunzell J.D., Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome, The Metabolic and Molecular Bases of Inherited Disease, pp. 1913-1932, (1995)

[5]

de Graaf J., Hendriks J.C., Demacker P.N., Stalenhoef A.F., Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment, Arterioscler Thromb, 13, pp. 712-719, (1993)

[6]

Adkins J.C., Faulds D., Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia, Drugs, 54, pp. 615-633, (1997)

[7]

Caslake M.J., Packard C.J., Gaw A., Et al., Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia, Arterioscler Thromb, 13, pp. 702-711, (1993)

[8]

Guerin M., Bruckert E., Dolphin P.J., Et al., Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia, Arterioscler Thromb Vasc Biol, 16, pp. 763-772, (1996)

[9]

Farnier M., Bonnefous F., Debbas N., Irvine A., Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia, Arch Intern Med, 154, pp. 441-449, (1994)

[10]

Gholami K., Tavakoli N., Maleki M., Shafiee A., Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia, J Clin Pharm Therapeutics, 23, pp. 213-221, (1998)

← 1 2 3 4 5 →